Project Name: Multiple Sclerosis (MS) Capacity Redesign Collaborative Working Project (“CWP”)

Project Summary:

The CWP aims to foster collaboration between Novartis and the CW Partner to enhance the multiple sclerosis service delivery for patients with relapsing remitting multiple sclerosis (RRMS). Through this partnership, the parties seek to leverage their combined expertise to improve patient outcomes and streamline healthcare processes. The ultimate goal is to develop innovative solutions that address the challenges faced by patients diagnosed with RRMS, and provide more efficient, effective care.

The primary focus of the CWP is to ensure timely treatment for RRMS patients, thereby attempting to minimise the future demand on the service resulting from disease relapse. The CWP intends to optimise patient care, improve treatment outcomes, and manage the increasing demand on MS services by implementing collaborative efforts between the CW Partner and Novartis with the addition of one full time equivalent (FTE) MS clinical nurse specialist band 7 and one FTE administrator band 4. The Collaborative Working Project (CWP) will undertake various tasks, including but not limited to additional clinics, and timely and complete administration tasks. Success of the CWP will be measured by the following KPIs:

  • A reduction in the number of RRMS patients requiring a review by the CW Partner’s MS service team from a baseline of 503, due to the clinic reviews in this CWP.
  • A reduction in the number of RRMS patients requiring a review >12 months by the CW Partner’s MS service team from a baseline of 503, due to the clinic reviews in this CWP.
  • An increase in the number of RRMS patients, currently on a low efficacy treatment (LET) or no treatment, having their medicines optimised in a clinic review from a baseline of 503, due to the clinic reviews in this CWP. 

By continuously monitoring these metrics, this CWP seeks to ensure tangible improvements in healthcare provision and patient well-being.

Milestones: 

Milestone 1: CWP kick-off meeting.

Milestone 2: Recruitment and onboarding of the CWP roles. 

Milestone 3 to 6: Commencement of data analysis for baseline measures. Clinic activity with data submission and CWP review every 3 months and the creation of a service protocol review at milestone 7. 

Milestone 8: CWP wrap up. CWP outcomes. 

Expected Benefits: 

Patient.

  • Appropriate and well-timed access to treatment and reduction in the time it takes for RRMS patients to access treatment.
  • Enhanced treatment decision-making.
  • Improved patient experience and satisfaction.
  • Equity of care: Driving equity of care for patients across hub and spoke sites within the South West London (SWL) area by reducing variations in care. CW Partner (i.e., NHS).

NHS.

  • Appropriate use of skill set across the service.
  • Accelerated access to services.
  • Improved quality of care.
  • Reduction in patient waiting lists.
  • Improved MDT efficiency and outcomes.
  • Improved experience of staff by spreading workload.

Novartis.

  • Novartis is likely to see positive outcomes as a result of the CWP with the CW Partner. By enhancing the multiple sclerosis service delivery, the CWP aims to improve patient outcomes for those patients with relapsing remitting multiple sclerosis (RRMS). As more patients are reviewed, there is potential for greater utilisation of Novartis's medicines, in line with national and local guidelines, where appropriate, leading to improved patient care.
  • Improved understanding of the real-world challenges, service pressure points and priorities associated with the MS service and backlog of patients pending reviews. This will enable Novartis to build better projects in this therapy area in other regions of the UK with an aim to help more RRMS patients receive a timely review.
  • Enhanced reputation and visibility: Collaborating with the CW Partner improving patient care can enhance Novartis's reputation and visibility within the healthcare community. This CWP will demonstrate commitment to making a meaningful impact on patient outcomes beyond the development and commercialisation of pharmaceutical products.

Start Date & Expected Duration: August 2025 for 21 months or CWP completion, whichever should first occur.

FA-11484404 | August 2025